SCHEMBL19259848

SCHEMBL19259848

CCCCC(CC)COC(=O)CCSc1cc(C(=O)O)cc(-c2cnn(C)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
TSHR P16473 3/20 0.42
ATM Q13315 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
LOXL2 Q9Y4K0 4/20 0.37
ALDH1A1 P00352 5/20 0.36
MAPK1 P28482 3/20 0.36
LMNA P02545 3/20 0.36
CA2 P00918 1/20 0.35
HSD17B10 Q99714 1/20 0.34
RECQL P46063 1/20 0.34
FGFR2 P21802 2/20 0.33
FGFR1 P11362 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32
EP300 Q09472 1/20 0.32
CREBBP Q92793 1/20 0.32
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19274747 0.91 CYP3A4 (0.41) CYP3A4TSHRATMTDP1ALDH1A1
SCHEMBL20983586 0.89 CYP3A4 (0.39) CYP3A4TSHRATMTDP1ALDH1A1
SCHEMBL29971193 0.89 CYP3A4 (0.39) CYP3A4TSHRATMTDP1ALDH1A1
SCHEMBL19259884 0.89 CYP3A4 (0.43) CYP3A4TSHRATMTDP1LOXL2
SCHEMBL29972024 0.89 CYP3A4 (0.43) CYP3A4TSHRATMTDP1LOXL2
SCHEMBL19259585 0.89 CYP3A4 (0.43) CYP3A4TSHRATMTDP1LOXL2
SCHEMBL19259732 0.89 CYP3A4 (0.43) CYP3A4TSHRATMTDP1LOXL2
SCHEMBL19259690 0.87 CYP3A4 (0.43) CYP3A4TSHRATMTDP1ALDH1A1
SCHEMBL19274653 0.86 CYP3A4 (0.41) CYP3A4TSHRATMTDP1LOXL2
SCHEMBL19259894 0.84 CYP3A4 (0.48) CYP3A4TSHRATMTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416956-B1 METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) 2024-04-10 EP disclosed
EP-3416956-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER The Institute of Cancer Research : The Royal Cancer Hospital (GB) 2018-12-26 EP disclosed
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed